DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Lestaurtinib
Lestaurtinib
Download
Download
FLT3 Inhibitors in Acute Myeloid Leukemia Mei Wu1, Chuntuan Li2 and Xiongpeng Zhu2*
Cytokine Signaling in Tumor Progression
Lestaurtinib Enhances the Antitumor Efficacy of Chemotherapy in Murine Xenograft Models of Neuroblastoma
AHRQ Healthcare Horizon Scanning System – Status Update Horizon
Staurosporine, an Inhibitor of Hormonally Up-Regulated Neu- Associated Kinase
Clinical Benefits and Safety of FMS-Like Tyrosine Kinase 3
Tyrosine Kinase Inhibitors for Solid Tumors in the Past 20 Years (2001–2020) Liling Huang†, Shiyu Jiang† and Yuankai Shi*
Adverse Renal Effects of Novel Molecular Oncologic Targeted Therapies: a Narrative Review
Stembook 2018.Pdf
Protein Kinase Inhibitors for Acute Leukemia Yuan Ling, Qing Xie, Zikang Zhang and Hua Zhang*
Lestaurtinib As a FLT3 Inhibitor Xdepartment of Haematology, School of Medicine, Cardiff University, UK
Targeting FLT3 Mutations in Acute Myeloid Leukemia
Small Molecules in Targeted Cancer Therapy: Advances, Challenges, and Future Perspectives
Genetic Modifiers of EGFR Dependence in Non-Small Cell Lung Cancer
NTRK1 Fusions for the Therapeutic Intervention of Korean Patients with Colon Cancer
F1H Soft Tissue Sarcoma (NOS) Sample Report.Pdf
Top View
Lund University Publications Institutional Repository of Lund University ______
Lestaurtinib Is a Potent Inhibitor of Anaplastic Thyroid Cancer Cell Line Models
(12) United States Patent (10) Patent No.: US 9,345,766 B2 Zhang Et Al
Targeting the FMS-Like Tyrosine Kinase 3 in Acute Myeloid Leukemia
Kinase Inhibitors As Anticancer Drugs
Identification of Therapeutic Targets in Ovarian Cancer Through Active Tyrosine Kinase Profiling
Crizotinib-Induced Immunogenic Cell Death in Non-Small Cell Lung Cancer
The Ups and Downs of STAT Inhibition in Acute Myeloid Leukemia
THERAPY CODES 4-Factor Concentrate F014 5A2A F017
The Fast Track to New Anti-Malarial Medicines?
Transient Exposure to Quizartinib Mediates Sustained Inhibition of FLT3 Signaling While Specifically Inducing Apoptosis in FLT3-Activated Leukemia Cells
Targeting Tyrosine Kinases in Acute Myeloid Leukemia: Why, Who and How?
BCAN-NTRK1 Fusion
(2006.01) C07d 413/14
FLT3 and KIT in Acute Myeloid Leukemia
( 12 ) Patent Application Publication
JAK/STAT Signaling
ITD Confer Resistance to Multiple Tyrosine Kinase Inhibitors
Oncology Drugs in the Pipeline
Pharmacological Inhibition of Oncogenic STAT3 and STAT5 Signaling in Hematopoietic Cancers
Oncompass Report NÉV Anonymous a Realtime Oncology Molecular Treatment Calculator Számításaival
Naval Daver, MD Assistant Professor Department of Leukemia the University of Texas MD Anderson Cancer Center Houston, Texas
1 Induction of Endoplasmic Reticulum Stress by Sorafenib and Activation Of
LOXO-101 Briefing Document for the 29 June 2016 Oncologic Drugs
Identification of Existing Drugs That Effectively Target NTRK1- and ROS1-Rearrangements in Lung Cancer Curtis R
Oncology Drugs in the Pipeline
Inhibition of FLT3 in AML: a Focus on Sorafenib
C-KIT Tyrosine Kinase in the Pathogenesis and Therapy of Core-Binding Factor-Related Acute Myeloid Leukaemia (AML)
Induction of Endoplasmic Reticulum Stress by Sorafenib and Activation of NF-Kb by Lestaurtinib As a Novel Resistance Mechanism in Hodgkin Lymphoma Cell Lines
Kinase Domain Mutations Confer Resistance to Novel Inhibitors Targeting JAK2V617F in Myeloproliferative Neoplasms
Regulation of FLT3 and Its Ligand in Normal Hematopoietic Progenitor Cells Katja C
Protein Tyrosine Kinase/RTK
Natural Product and Natural Product Derived Drugs in Clinical Trials
FLT3 Inhibitors for the Treatment of Acute Myeloid Leukemia
Overcoming Resistance to FLT3 Inhibitors in the Treatment of FLT3-Mutated AML